Completed PHASE1 INTERVENTIONAL 1-arm NCT00705653

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

A Phase I Study of CGC-11047 in Subjects With Advanced Refractory Solid Tumors

Sponsor: Progen Pharmaceuticals

Conditions Cancer

Interventions PG-11047

Updated 8 times since 2017 Last updated: Mar 21, 2012 Started: Mar 31, 2005 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00705653, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by Progen Pharmaceuticals, it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Progen Pharmaceuticals

Data source: Progen Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States